What question did this study set out to answer?

This study aims to evaluate the clinical outcomes of Medicare beneficiaries with CLL treated with first-line BTK inhibitors.

May 29, 2026Journal of Clinical Oncology

Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL).

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the clinical outcomes of Medicare beneficiaries with CLL treated with first-line BTK inhibitors.
Utilized a large Medicare Fee-For-Service database for analysis.
Retrospective cohort study included patients aged ≥65 diagnosed with CLL from 01/01/2020 to 06/30/2025.
Outcomes measured included overall survival, time to next treatment, and treatment discontinuation using survival probability methods.
Zanubrutinib showed better overall survival and treatment outcomes compared to ibrutinib and acalabrutinib.
At 12 months, survival rates were 91% for zanubrutinib compared to 85% for ibrutinib and 87% for acalabrutinib.
After adjusting for baseline factors, zanubrutinib had a significantly lower risk of death and treatment discontinuation compared to both ibrutinib and acalabrutinib.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study evaluates better survival outcomes with zanubrutinib in older Medicare beneficiaries with CLL, suggesting efficacy in treatment plans.

Cite This Study

Ermann et al. (2026) studied this question.

synapsesocial.com/papers/6a192d7efab5b468c441665a https://doi.org/10.1200/jco.2026.44.16_suppl.7047

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study evaluates better survival outcomes with zanubrutinib in older Medicare beneficiaries with CLL, suggesting efficacy in treatment plans.

Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL).

Key Points

Discussion

Implication

Cite This Study

Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL).

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider